详情页 - 河北大学附属医院知识库

当前位置：首页 > 详情页

Modulators for palmitoylation of proteins and small molecules

7| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Key Laboratory of Pharmaceutical Quality Control of Hebei Province, College of Pharmaceutical Sciences, Hebei University, Baoding, 071002, China [2]Key Laboratory of Medicinal Chemistry and Molecular Diagnosis, Ministry of Education, Hebei University, Baoding, Hebei, 071002, China [3]Department of hematopathology, Affiliated Hospital of Hebei University, Hebei University, Baoding, 071002, China

出处：

DOI：

ISSN：

关键词： Palmitoylation Palmitoyltransferases Depalmitoylases Inhibitors

摘要：

As an essential form of lipid modification for maintaining vital cellular functions, palmitoylation plays an important role in in the regulation of various physiological processes, serving as a promising therapeutic target for diseases like cancer and neurological disorders. Ongoing research has revealed that palmitoylation can be categorized into three distinct types: N-palmitoylation, O-palmitoylation and S-palmitoylation. Herein this paper provides an overview of the regulatory enzymes involved in palmitoylation, including palmitoyltransferases and depalmitoylases, and discusses the currently available broad-spectrum and selective inhibitors for these enzymes.Copyright © 2024 Elsevier Masson SAS. All rights reserved.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

无

最新[2025]版：

大类 | 2 区医学

小类 | 1 区药物化学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 CHEMISTRY, MEDICINAL

影响因子： 6 最新[2023版] 6.1 最新五年平均 0 出版当年[2024版] 0 出版当年五年平均 6 出版前一年[2023版]

第一作者：

第一作者机构： [1]Key Laboratory of Pharmaceutical Quality Control of Hebei Province, College of Pharmaceutical Sciences, Hebei University, Baoding, 071002, China

通讯作者：

通讯机构： [1]Key Laboratory of Pharmaceutical Quality Control of Hebei Province, College of Pharmaceutical Sciences, Hebei University, Baoding, 071002, China [2]Key Laboratory of Medicinal Chemistry and Molecular Diagnosis, Ministry of Education, Hebei University, Baoding, Hebei, 071002, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]New protein tyrosine phosphatase inhibitors from fungus Aspergillus gorakhpurensis F07ZB1707 [2]Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials [3]Pituitary-related immune adverse events induced by programmed death Protein-1 inhibitors differ clinically from hypophysitis [4]Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma [5]ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors [6]Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis [7]Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis [8]Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis [9]Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis [10]Clinical efficacy and safety of transarterial chemoembolization combined with targeted therapy and PD1 inhibitors in patients with advanced liver cancer